Skip to main content
OpenTrials
Completed

NCT Number: NCT03935230

Uncontrolled Donation After Circulatory Determination of Death (uDCDD)

World-wide, patients waiting for organ transplantation exceed the number of organs available. Many European countries have a uDCDD program which contribute to 10-15% of the donor pool. In Canada, this type of program does not exist. The purpose of this study is to report how many deceased person fulfill the criteria for uncontrolled DCDD in a Canadian medical center.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

About this study

While transplantation has become the definitive treatment for many people suffering end-stage organ failure, demand exceeds supply. For many years, donation after neurological death represented the principal source of organs for transplantation. In the last decade, prevention measures, improvements in neurocritical care, and decompressive craniectomy have led to a significant decrease in the number of non-directed donors (NDDs). In such situations, alternative sources for organ donation must be identified. Cardiac-arrest patients could provide a solution to this organ shortage. Patients who have experienced unexpected in or out of hospital cardiopulmonary arrest could become organ donors. Organ donation following uncontrolled cardiocirculatory death is currently practiced in many European countries. However, in Canada, it's not yet authorized. Yet, each deceased could save up to four lives. The purpose of this study is to determine the organ potential for a cohort of patient who had died from a cardiopulmonary arrest at the CHUS in 2015 and assess the effect of the implementation of a uDCD program on the number of additional donors.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients treated for cardiocirculatory arrest at the CIUSSS-Estrie CHUS in 2015.

Exclusion criteria

  • Patients with a status of no resuscitation
  • Pediatric patients (<18 years old)
  • Adults >65 years old

Treatment and study plan

Primary outcomes

  1. Potential contribution of a uDCDD program on the number of additional donors.

    Time frame: 1 year

    Defined as (must meet all criteria):

    • Age ≤70 years old
    • Absence of obvious cause of death (rigor mortis, decapitation, overwhelming traumatic injury)
    • Absence of surgical cause of cardiac arrest
    • No sign of IV drug abuse
    • No history of malignancies

Secondary outcomes

  1. Effect of the implementation of a uDCDD program on the number of additional organs suitable for transplantation.

    Time frame: 1 year

    Effect of the implementation of a uDCDD program on the number of additional organs suitable for transplantation.

  2. Number of tissus donors

    Time frame: 1 year

    Number of tissus donors

  3. Potential obstacles and solutions related to the implementation of a uDCDD program in Canada.

    Time frame: 1 year

    Potential obstacles and solutions related to the implementation of a uDCDD program in Canada.

  4. Areas of future research.

    Time frame: 1 year

    Areas of future research.

Sponsors and collaborators

Lead sponsor

Université de Sherbrooke

Other

Registry information

Official study title

Uncontrolled Donation After Circulatory Determination of Death (uDCDD): A Potential Solution to the Shortage of Organs in Quebec?

Acronym: uDCDD

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
May 2, 2019
Registry last updated
May 2, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.